CD4 and neoplasm: In melanoma, this approach revealed superior anti-tumor efficacy of rigosertib over anti-PD-1 therapy, including improved modulation of CD8+/CD4+ T cell ratios, highlighting the need for optimized immune-editing models to accurately assess therapeutic responses [202].